<p>MAIA Biotechnology, Inc.（NYSEAMERICAN:MAIA - 获取免费报告）在 12 月份的空头头寸显著增加。截至 12 月 15 日，空头头寸总计为 1,685,137 股，比 11 月 30 日的 687,986 股增加了 144.9%。目前，该股票的 6.7% 股份被卖空。根据平均每日交易量 1,479,960 股，当前的覆盖天数比率为 1.1 天。</p>
<p>获取 <strong>MAIA Biotechnology</strong> 警报：</p>
<h2>MAIA Biotechnology 的内部买卖</h2>
<p>在相关消息中，董事 Ngar Yee Louie 于 12 月 22 日星期一购买了 81,699 股 MAIA Biotechnology 股票，交易的平均成本为每股 1.22 美元，总价值为 99,672.78 美元。购买完成后，该董事持有公司 1,248,888 股股票，价值为 1,523,643.36 美元。这代表其持股增加了 7.00%。该交易在证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，董事 Stan Smith 于 12 月 22 日星期一购买了 57,189 股公司的股票，平均成本为每股 1.22 美元，总交易额为 69,770.58 美元。购买完成后，该董事直接持有公司 1,421,478 股，价值约为 1,734,203.16 美元。这笔交易代表其持股增加了 4.19%。有关此次购买的更多细节可在官方 SEC 披露中找到。过去 90 天内，内部人士共购买了 368,352 股公司股票，价值为 427,192 美元。内部人士持有公司 32.32% 的股份。</p>
<h2>对 MAIA Biotechnology 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近买卖了该股票的股份。Centerpoint Advisory Group 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为 28,000 美元。Geode Capital Management LLC 在第二季度将其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前持有 222,183 股公司股票，价值为 400,000 美元，此前在该期间内又购买了 7,746 股。Centric Wealth Management 在第二季度将其在 MAIA Biotechnology 的股份增加了 740.2%。Centric Wealth Management 目前持有 573,398 股公司股票，价值为 1,032,000 美元，此前在该期间内又购买了 505,150 股。Marshall Wace LLP 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为 29,000 美元。最后，Jane Street Group LLC 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为 52,000 美元。目前，5.65% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>MAIA Biotechnology 股票上涨 6.1%</h2>
<p>在周五的交易中，NYSEAMERICAN MAIA 的股票上涨了 0.09 美元，达到 1.57 美元。该公司的交易量为 761,956 股，而其平均交易量为 977,358 股。该股票的市值为 5814 万美元，市盈率为-2.15。MAIA Biotechnology 的 12 个月低点为 0.87 美元，12 个月高点为 2.74 美元。该公司的 50 日移动平均线为 1.22 美元，200 日移动平均线为 1.50 美元。</p>
<p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 获取免费报告）最后一次发布季度财报是在 11 月 7 日星期五。该公司报告本季度每股收益为（0.27 美元），低于市场共识预期的（0.19 美元）0.08 美元。分析师预计 MAIA Biotechnology 在当前年度的每股收益将为-1.3。</p>
<h2>关于 MAIA Biotechnology</h2>
<p>（获取免费报告）</p>
<p>MAIA Biotechnology, Inc 是一家临床阶段的生物制药公司，开发一种专有平台，用于单克隆抗体与诊断和治疗放射性同位素的特异性结合。通过利用精确放射化学，该公司旨在增强基于抗体的成像剂和靶向放射治疗的安全性和有效性。其方法旨在通过 PET 成像提供高对比度的肿瘤可视化，并在肿瘤学适应症中实现集中细胞毒性。</p>
<p>该公司的产品管线包括多个抗体 - 放射示踪剂候选药物，经过优化以检测不同的肿瘤生物标志物，临床前数据表明其靶向特异性和药代动力学优于传统方法。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 MAIA Biotechnology</li>
<li>华盛顿为战争做准备</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>开火正式开始……</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MAIA Biotechnology 吗？</h2>
<p>在你考虑 MAIA Biotechnology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MAIA Biotechnology 并不在名单上。</p>
<p>虽然 MAIA Biotechnology 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

MAIA

<p>MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) 在 12 月份的空头头寸增加了 144.9%，总计达到 1,685,137 股。目前，该公司的 6.7% 股份被做空，空头头寸比率为 1.1 天。内部人士购入了大量股份，董事们进行了显著的增持。该股票上涨了 6.1%，达到 1.57 美元，市值为 5814 万美元。MAIA Biotechnology 是一家临床阶段的生物制药公司，专注于单克隆抗体和放射治疗药物</p>

<p>MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,685,137 shares, an increase of 144.9% from the November 30th total of 687,986 shares. Currently, 6.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Currently, 6.7% of the shares of the stock are sold short.</p>
<div class="lb-trans"><p>MAIA Biotechnology, Inc.（NYSEAMERICAN:MAIA - 获取免费报告）在 12 月份的空头头寸显著增加。截至 12 月 15 日，空头头寸总计为 1,685,137 股，比 11 月 30 日的 687,986 股增加了 144.9%。目前，该股票的 6.7% 股份被卖空。根据平均每日交易量 1,479,960 股，当前的覆盖天数比率为 1.1 天。</p>
</div><p>Get <strong>MAIA Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>MAIA Biotechnology</strong> 警报：</p>
</div><h2>Insider Buying and Selling at MAIA Biotechnology</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 的内部买卖</h2>
</div><p>In related news, Director Ngar Yee Louie acquired 81,699 shares of MAIA Biotechnology stock in a transaction dated Monday, December 22nd. The shares were purchased at an average cost of $1.22 per share, with a total value of $99,672.78. Following the completion of the purchase, the director owned 1,248,888 shares of the company's stock, valued at $1,523,643.36. This represents a 7.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, Director Stan Smith purchased 57,189 shares of the firm's stock in a transaction on Monday, December 22nd. The stock was bought at an average cost of $1.22 per share, for a total transaction of $69,770.58. Following the completion of the purchase, the director directly owned 1,421,478 shares in the company, valued at approximately $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 368,352 shares of company stock valued at $427,192 over the last ninety days. Insiders own 32.32% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Ngar Yee Louie 于 12 月 22 日星期一购买了 81,699 股 MAIA Biotechnology 股票，交易的平均成本为每股 1.22 美元，总价值为 99,672.78 美元。购买完成后，该董事持有公司 1,248,888 股股票，价值为 1,523,643.36 美元。这代表其持股增加了 7.00%。该交易在证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，董事 Stan Smith 于 12 月 22 日星期一购买了 57,189 股公司的股票，平均成本为每股 1.22 美元，总交易额为 69,770.58 美元。购买完成后，该董事直接持有公司 1,421,478 股，价值约为 1,734,203.16 美元。这笔交易代表其持股增加了 4.19%。有关此次购买的更多细节可在官方 SEC 披露中找到。过去 90 天内，内部人士共购买了 368,352 股公司股票，价值为 427,192 美元。内部人士持有公司 32.32% 的股份。</p>
</div><h2>Hedge Funds Weigh In On MAIA Biotechnology</h2>
<div class="lb-trans"><h2>对 MAIA Biotechnology 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Centerpoint Advisory Group purchased a new stake in MAIA Biotechnology in the second quarter worth about $28,000. Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company's stock valued at $1,032,000 after acquiring an additional 505,150 shares during the period. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter worth approximately $29,000. Finally, Jane Street Group LLC bought a new stake in MAIA Biotechnology during the 2nd quarter worth approximately $52,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买卖了该股票的股份。Centerpoint Advisory Group 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为 28,000 美元。Geode Capital Management LLC 在第二季度将其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前持有 222,183 股公司股票，价值为 400,000 美元，此前在该期间内又购买了 7,746 股。Centric Wealth Management 在第二季度将其在 MAIA Biotechnology 的股份增加了 740.2%。Centric Wealth Management 目前持有 573,398 股公司股票，价值为 1,032,000 美元，此前在该期间内又购买了 505,150 股。Marshall Wace LLP 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为 29,000 美元。最后，Jane Street Group LLC 在第二季度购买了 MAIA Biotechnology 的新股份，价值约为 52,000 美元。目前，5.65% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>MAIA Biotechnology Stock Up 6.1%</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 股票上涨 6.1%</h2>
</div><p>Shares of NYSEAMERICAN MAIA traded up $0.09 during trading on Friday, reaching $1.57. The company had a trading volume of 761,956 shares, compared to its average volume of 977,358. The stock has a market cap of $58.14 million and a PE ratio of -2.15. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $2.74. The business's 50-day moving average is $1.22 and its 200 day moving average is $1.50.</p>
<div class="lb-trans"><p>在周五的交易中，NYSEAMERICAN MAIA 的股票上涨了 0.09 美元，达到 1.57 美元。该公司的交易量为 761,956 股，而其平均交易量为 977,358 股。该股票的市值为 5814 万美元，市盈率为-2.15。MAIA Biotechnology 的 12 个月低点为 0.87 美元，12 个月高点为 2.74 美元。该公司的 50 日移动平均线为 1.22 美元，200 日移动平均线为 1.50 美元。</p>
</div><p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.08). On average, analysts anticipate that MAIA Biotechnology will post -1.3 earnings per share for the current year.</p>
<div class="lb-trans"><p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 获取免费报告）最后一次发布季度财报是在 11 月 7 日星期五。该公司报告本季度每股收益为（0.27 美元），低于市场共识预期的（0.19 美元）0.08 美元。分析师预计 MAIA Biotechnology 在当前年度的每股收益将为-1.3。</p>
</div><h2>About MAIA Biotechnology</h2>
<div class="lb-trans"><h2>关于 MAIA Biotechnology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.</p>
<div class="lb-trans"><p>MAIA Biotechnology, Inc 是一家临床阶段的生物制药公司，开发一种专有平台，用于单克隆抗体与诊断和治疗放射性同位素的特异性结合。通过利用精确放射化学，该公司旨在增强基于抗体的成像剂和靶向放射治疗的安全性和有效性。其方法旨在通过 PET 成像提供高对比度的肿瘤可视化，并在肿瘤学适应症中实现集中细胞毒性。</p>
</div><p>The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个抗体 - 放射示踪剂候选药物，经过优化以检测不同的肿瘤生物标志物，临床前数据表明其靶向特异性和药代动力学优于传统方法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than MAIA Biotechnology</li>
<li>Washington prepares for war</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Shots officially fired…</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MAIA Biotechnology</li>
<li>华盛顿为战争做准备</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>开火正式开始……</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MAIA Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MAIA Biotechnology 吗？</h2>
</div><p>Before you consider MAIA Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MAIA Biotechnology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MAIA Biotechnology 并不在名单上。</p>
</div><p>While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MAIA Biotechnology 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

MAIA Biotech 公司（NYSEAMERICAN:MAIA）在 12 月份的空头头寸增加了 144.9%